Alnylam, Medicines Co. tout early results for RNAi PCSK9 contender; Ex-Prosensa chief joins Asceneuron;

@FierceBiotech: KIT team points pancreatic cancer therapy toward clinical trials. FierceBiotechResearch article | Follow @FierceBiotech

@JohnCFierce: Ex-Lumena gang pilots new course at Amplyx with antifungal R&D, $40.5M. Report | Follow @JohnCFierce

@DamianFierce: $HZNP "is threatening $ESRX's profiteering and exposing ... a lack of care for patients and respect for physicians." Release | Follow @DamianFierce

> Alnylam Pharmaceuticals ($ALNY) and partner the Medicines Company ($MDCO) said their in-development RNAi treatment charted a sustained reduction of bad cholesterol in an ongoing Phase I trial. Like recently approved medicines from Sanofi ($SNY) and Amgen ($AMGN), the medicine targets PCSK9 to slash LDL cholesterol but is designed to be dosed much less frequently. More

> Hans Schikan, the former CEO of Prosensa, has been named chairman of Switzerland's Asceneuron. Release

> Zurich-based Kuros Biosurgery AG has added CHF 5 million to its latest fundraising, bringing the total to CHF 20 million. Release

> As Sanofi struggles to keep its diabetes business competitive, rival Novo Nordisk ($NVO) is snatching up more market share. Story

Medical Device News

@FierceMedDev: Medtronic reports strong leadless pacemaker data as it races St. Jude to FDA approval. More | Follow @FierceMedDev

@VarunSaxena2: IYCMI from FierceDrugDelivery: Physicians call for novel abuse-deterrent opioid agonist/antagonist formulations in survey. Article | Follow @VarunSaxena2

@EmilyWFierce: Theranos and Safeway split after $350M deal, code-named "T-Rex," falls through. More from the WSJ | Follow @EmilyWFierce

> AliveCor adds former Google exec as CEO to further consumer ECG push. Articles

> Stanford engineers develop touch-free ultrasound device for tumor detection. More

Pharma News

@FiercePharma: GeneOne, Inovio's MERS vaccine enters PhI at Walter Reed. Story | Follow @FiercePharma

@EricPFierce: ICYMI: #Novo makes sure Denmark gets some of the action as it starts massive build up. More | Follow @EricPFierce

@CarlyHFierce: $GSK shoots for diabetes-esque platform approach with new respiratory med in hand. Article | Follow @CarlyHFierce

> Bondholders bail on Valeant amid cash flow concerns. More

> Sources: Novartis faces yet another sanction in Japan. Article

Biotech Research News

> MD Anderson group tracks 'modest' impact of lymphoma drug. Item

> Warp Drive Bio constructs a new cancer R&D tech platform. Story

> Microbiome study highlights bacterial strategy for treating severe diarrhea. News

> Case Western researchers spotlight role of rapid protein movement in hearing loss. More

> KIT team points pancreatic cancer therapy toward clinical trials. Article

Vaccines News

> GeneOne, Inovio's MERS vaccine enters PhI at Walter Reed. News

> MenAfriVac succeeds in sub-Saharan Africa, but the fight isn't over yet. More

> James Cook University researcher wins $2M Gates grant for malaria vaccine development. Story

> Novavax kicks off PhIII trial for its RSV vaccine. Article

> EMA safety review raises no issues with HPV vaccines from Merck, GSK. Report

Pharma Marketing News

> $1-per-pill alternative to Turing drug gets 'overwhelming' response: Imprimis CEO. Article

> Medivation's Xtandi sales force due for hiring, revamp as urology push falls flat. Report

> GSK shoots for diabetes-esque platform approach with new respiratory med in hand. More

> Allergan counting on January formulary boost to jump-start Namzaric launch. Story

> AstraZeneca holds on to purple Nexium trademark with early court win. Article

Suggested Articles

Avidity Biosciences is on a roll—after inking an R&D deal with Eli Lilly and hiring a new CEO, the company is reeling in $100 million.

What the NASH field needs, says Genfit CEO Pascal Prigent, is something like the Hb1Ac test for diabetes.

Blocking a newly discovered molecule produced by B cells could slow their flow into the brain and offer a new way to treat MS, a Canadian team found.